---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-024537"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2023-07-14T23:59:59+00:00"
generated_at: "2026-06-13T08:06:45.861206+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MyMD still awaiting Phase 2 data for MYMD-1 sarcopenia trial completed June 2023

## Summary
- Phase 2 trial of MYMD-1 for sarcopenia completed in June 2023; data not received as of July 14.
- No guidance on timing of data release; company states it is 'still awaiting receipt.'
- No other material updates in this filing; stock trades on Nasdaq under ticker MYMD.

## SEC filing metadata
- accession: 0001493152-23-024537
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2023-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315223024537/0001493152-23-024537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315223024537/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-024537
- JSON: https://secwatch.observer/filing/0001493152-23-024537.json
- Plain text: https://secwatch.observer/filing/0001493152-23-024537.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.